Argenica Therapeutics LtdASX: AGN

Concussion Data Selected for Neurotrauma Congress

Sep 14, 2026 at 6:12 PM EDT · Issued by Argenica Therapeutics Ltd via ASX

Filed with ASX · Sep 14, 2026 at 6:12 PM EDT

On 6ix: 6ix.com/news/concussion-data-selected-for-neurotrauma-congress

ASX ANNOUNCEMENT Argenica Therapeutics Limited (ACN 637 578 753) ¦ASX: AGN Unit 4, 117 Broadway Nedlands WA 6009 ¦+618 9329 3396 www.argenica.com.au XARANETIDE CONCUSSION DATA SELECTED FOR ORAL PRESENTATION AT INTERNATIONAL NEUROTRAUMA CONGRESS Perth, Australia; 15 September, 2026 -...

View Attachment

6ix hasn’t read this filing yet.

Argenica Therapeutics Ltd on 6ix

Earlier from Argenica Therapeutics

Appendix 4E & Annual Report to 30 June 2026Aug 26
Appendix 4G & Corporate Governance StatementAug 26
Notification of cessation of securities - AGNAug 13
ARG007 Shows Significant Neuroprotection in Concussion StudyJul 15
ARG007 (Xaranetide) Completes All Three FDA Requested AssaysJun 10

Later from Argenica Therapeutics

AGM Date & Closing Date for Director NominationsSep 22
Change of Director's Interest NoticeSep 28
Notice of Annual General Meeting/Proxy FormOct 19
New Mechanism Findings Offer Insights Into Phase 2 SignalOct 19
Quarterly Activities/Appendix 4C Cash Flow ReportOct 29

All Argenica Therapeutics news releases

Follow Argenica Therapeutics into a list and get an email when it puts out news.

Follow Argenica Therapeutics